XTalks

APRIL 22, 2022

Flow cytometric receptor occupancy assays are being increasingly used in preclinical and clinical studies. Both the areas of drug development and clinical trials are increasingly using in vitro assays to help determine the efficacy of an investigational therapeutic. The Benefits of Receptor Occupancy in Clinical Trials.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Antibody 98

XTalks

SEPTEMBER 2, 2020

NAFLD is part of the metabolic syndrome that is characterized by diabetes, or pre-diabetes (insulin resistance), which includes being overweight or obese, elevated blood lipids such as cholesterol and triglycerides, as well as high blood pressure. NASH may result in severe liver scarring and cirrhosis.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Insulin 98

XTalks

NOVEMBER 22, 2022

In clinical trials, the treatment delayed stage 3 disease onset for about two years compared with the placebo. Type 1 diabetes, also known as insulin-dependent or juvenile diabetes, is an autoimmune disease that occurs when the body is unable to make enough insulin due to destruction of the beta insulin-producing cells in the pancreas.

Insulin 97

Insulin Drugs FDA Approval Immune Response 97

XTalks

SEPTEMBER 15, 2020

A vaccine developed by Swedish company Diamyd Medical has demonstrated significant treatment efficacy in a predefined genetic subgroup of individuals with type 1 diabetes in a Phase IIb clinical trial. Diamyd Medical is a clinical-stage biopharmaceutical company that develops therapies for type 1 diabetes. The DIAGNODE-2 Trial.

Vaccine 103

Vaccine Vaccination Insulin Trials 103

XTalks

APRIL 15, 2025

In the pancreas, potassium channels regulate insulin secretion. Vykay XR Clinical Trial Results Data from a randomized, placebo-controlled Phase III trial (Study 2-RWP or Study C602-RWP) support Vykat XRs approval. Based on the average weight of patients in its clinical trials, Vykat XR will cost $466,200 per year.

FDA Approval 52

FDA Approval Clinical Trials Clinical Trials Trials 52

XTalks

NOVEMBER 23, 2022

Subscribe to the Xtalks Life Science Podcast to never miss a new episode. Pfizer Shares Positive Phase III Data for Maternal RSV Vaccine Candidate. The weekly podcast is available for streaming every Wednesday on Spotify , Apple Music and wherever you stream your podcasts.

Life Science 52

Life Science FDA Approval Vaccine Vaccination 52

XTalks

DECEMBER 13, 2024

Petrelintide, administered once a week under the skin, targets obesity through its action as an amylin analog, a hormone co-secreted with insulin from the pancreas. And among its many obesity drugs in clinical trials, Eli Lillys amylin analog eloralintide is in Phase II.

Drugs 102

Drugs Hormones Trials Clinical Trials 102

XTalks

JULY 15, 2024

The drug has been evaluated in five clinical trials for PBH. Congenital HI is a genetic disorder that causes excessive insulin production by the pancreas, which lowers plasma or blood sugar. This action helps mitigate hypoglycemia by reducing insulin secretion and stabilizing glucose levels.

Drugs 52

Drugs Insulin Life Science Marketing 52

XTalks

JULY 15, 2024

The drug has been evaluated in five clinical trials for PBH. Congenital HI is a genetic disorder that causes excessive insulin production by the pancreas, which lowers plasma or blood sugar. This action helps mitigate hypoglycemia by reducing insulin secretion and stabilizing glucose levels.

Insulin 52

Insulin Drugs Life Science Marketing 52

XTalks

JULY 17, 2024

Octreotide is a synthetic analog of somatostatin, a hormone in the body that inhibits the release of several other hormones, including growth hormone (GH), glucagon and insulin. Excess GH stimulates the secretion of insulin-like growth factor-1 (IGF-1) from the liver, which causes most of the clinical manifestations of acromegaly.

Trials 59

Trials Hormones Clinical Trials Clinical Trials 59

XTalks

FEBRUARY 6, 2024

Revita, an outpatient endoscopic procedural therapy, which aims to eliminate insulin needs and enhance glycemic control by ablating dysfunctional duodenal mucosa. Fractyl Health’s common stock commenced trading on the Nasdaq Global Market under the ticker symbol “GUTS” on February 2, 2024.

Gene Therapy 98

Gene Therapy Gene Clinical Trials Clinical Trials 98

XTalks

FEBRUARY 21, 2024

Clinical Trials for MASH Treatment The tirzepatide trial involved approximately 190 adults with MASH at different stages. There are also ongoing clinical trials that are exploring its potential applications in cardiovascular disease and NASH. It has been approved for treating diabetes and obesity.

Clinical Trials 59

Clinical Trials Clinical Trials Trials Insulin 59

XTalks

APRIL 29, 2022

Eli Lilly announced that its obesity drug tirzepatide has scored favorably in a late-stage clinical trial, with results showing that people who took the drug lost an average of 50 pounds, or 21 percent, of their body weight compared to placebo.

Trials 98

Trials Drugs FDA Approval Clinical Trials 98

XTalks

JANUARY 25, 2023

Brenzavvy’s approval was based on an impressive amount of data collected from 23 clinical trials involving over 5,000 patients with type 2 diabetes. TheracosBio will thus be going up against some major market competition.

FDA Approval 52

FDA Approval Drugs Life Science Cosmetics 52

XTalks

SEPTEMBER 17, 2020

Acromegaly Surrogate Endpoint: Serum growth hormone and serum insulin-like growth factor 1 (IGF-1) are acceptable surrogate endpoints for acromegaly clinical trials involving somatostatin analogs such as octreotide, lanreotide and pasireotide. Also known as Berardinelli-Seip syndrome, there are four subtypes of lipodystrophy.

Trials 98

Trials Gene Hormones Clinical Trials 98

XTalks

JUNE 12, 2023

Medtronic’s proactive stance towards R&D is evident from the over 230 clinical trials it conducted and the more than 200 regulatory approvals it received in the US, Europe, Japan and China in the 2022 fiscal year. Internationally, Medtronic expanded its MiniMed 780G insulin pump and Guardian 4 sensor.

FDA Approval 98

FDA Approval Production Sales In-Vitro 98

XTalks

NOVEMBER 21, 2024

These gut hormones are released in response to nutrient intake and play a crucial role in the incretin effect, which enhances insulin secretion. It’s the first and only approved dual agonist targeting both the GIP and GLP-1 receptors. Researchers monitored a range of health metrics, including fasting glucose, HbA1c levels and weight changes.

Sales 105

Sales Insulin Drugs Trials 105

XTalks

FEBRUARY 8, 2021

Last year, Biocon Biologics and Mylan announced they’d be seeking interchangeable status for their long-acting insulin product Semglee , developed to be an alternative to Sanofi’s Lantus (insulin glargine). MYTH: Treatment-experienced patients cannot be prescribed biosimilars.

Production 78

Production Insulin Branding Generic Drugs 78

XTalks

FEBRUARY 8, 2024

Diabetes remains a critical global challenge, affecting millions of lives and commanding significant attention from the medical, life sciences and pharmaceutical sectors. In its 2022 financial report, Sanofi reported that sales of the long-acting insulin dropped 27.6 percent in the fourth quarter and decreased 56.7 from $289.36.

Sales 52

Sales Insulin FDA Approval Drugs 52

XTalks

NOVEMBER 9, 2022

GLP-1 receptor agonists, or incretin (metabolic hormones) mimetics, are analogs of the GLP-1 peptide hormone that binds to the GLP-1 receptor to regulate blood sugar levels by boosting insulin secretion. dependent insulin secretion and suppression of glucagon release. mediated glucose?dependent Mounjaro Versus Ozempic.

Insulin 98

Insulin Hormones FDA Approval Sales 98

XTalks

JUNE 10, 2024

The study explored efruxifermin’s potential in reducing liver fat, reversing fibrosis, enhancing insulin sensitivity and improving lipid profiles, representing a comprehensive treatment strategy for MASH. It not only reduces liver fat and inflammation but can also reverse fibrosis, enhance insulin sensitivity and improve lipid profiles.

Insulin 52

Insulin Life Science Regulation Hormones 52

XTalks

SEPTEMBER 22, 2020

The study investigators conducted a post-hoc analysis of data from the Phase III CANVAS Clinical Trial Program. Compared to other anti-diabetic drugs, such as sulfonylurea derivatives and insulin, SGLT2 inhibitors are associated with a low risk of hypoglycaemia.

Trials 95

Trials Clinical Trials Clinical Trials Insulin 95

XTalks

DECEMBER 15, 2022

In September 2021, the US Food and Drug Administration (FDA) issued a partial US clinical hold on the phase III DIAGNODE-3 clinical trial of the drug. XTALKS WEBINAR: The Clinical Trial Diversity Puzzle: How can the Industry do Better? Live and On-Demand: Thursday, January 26, 2023, at 1pm EST (10am PST).

Clinical Trials 97

Clinical Trials Clinical Trials Vaccine Vaccination 97

XTalks

MARCH 8, 2021

GLP-1 receptor agonists lower blood glucose levels by increasing the production of insulin. GLP-1 receptor agonists mimic the action of GLP-1, an intestinal hormone that stimulates the secretion of insulin when blood glucose levels rise. GLP-1 acts on GLP-1 receptors on insulin-producing pancreatic ? SURPASS-2 Clinical Trial.

Insulin 98

Insulin Hormones Clinical Trials Clinical Trials 98

XTalks

AUGUST 17, 2020

Cue Biopharma is a Cambridge, Massachusetts-based clinical-stage biotechnology company that is focused on developing injectable immune biologics using its proprietary Immuno-STAT (Selective Targeting and Alteration of T cells) platform. Promising Clinical Results. Cell-Based Immunotherapy vs. Immune Biologics. “The

Protein 98

Protein Engineer Immune Response In-Vivo 98

XTalks

AUGUST 2, 2023

It is a dipeptidyl peptidase-4 inhibitor that keeps insulin levels stable and reduces the amount of glucose produced by the body. 5) Toujeo (insulin glargine) Toujeo is very similar to Lantus in that both are insulin glargine, except Toujeo is more concentrated. Merck’s total global revenue from Lagevrio was $5.68 billion ($8.72

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

MAY 20, 2022

Life science industry data analytics company Evaluate Vantage predicts that Mounjaro could bring in $4.9 Mounjaro’s FDA approval was based on data from five clinical trials either as a single therapy or in combination with other diabetes medications. percent more than insulin degludec and 1.0

Insulin 52

Insulin Life Science Drugs Sales 52

XTalks

DECEMBER 3, 2024

In this blog, we take a closer look at the top 10 diabetes medications based on recent sales trends, exploring the factors behind their success, key clinical benefits and their broader impact on patient care. Price of Insulin: Varies significantly by type and brand of insulin. The company is targeting revenue of $40.4

Sales 105

Sales Insulin FDA Approval Drugs 105